Title: Ivermectin and gynecologic cancer: What's the data? - PubMed URL Source: https://pubmed.ncbi.nlm.nih.gov/40851910/ Markdown Content: Review ## Ivermectin and gynecologic cancer: What's the data? Vaidehi Mujumdar et al. Gynecol Oncol Rep.2025. Display options Format Display options Format ## Abstract •Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin's safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers. **Keywords:** Anti-helminthic; COVID-19; Gynecologic cancers; Ivermectin; Wonder drug. © 2025 The Authors. Published by Elsevier Inc. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy.](https://pubmed.ncbi.nlm.nih.gov/39585722/) Manavi MA, Mohammad Jafari R, Shafaroodi H, Sharifzadeh M, Dehpour AR.Manavi MA, et al.Epilepsia Open. 2025 Feb;10(1):361-367. doi: 10.1002/epi4.13107. Epub 2024 Nov 25.Epilepsia Open. 2025.PMID: 39585722 Free PMC article.Review. * [Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions.](https://pubmed.ncbi.nlm.nih.gov/35147927/) Molnar A, Lau S, Berges M, Masa RB, Solano JJ, Alter SM, Clayton LM, Shih RD, DeMets DL, Maki DG, Hennekens CH.Molnar A, et al.Ther Innov Regul Sci. 2022 May;56(3):382-385. doi: 10.1007/s43441-022-00378-0. Epub 2022 Feb 11.Ther Innov Regul Sci. 2022.PMID: 35147927 Free PMC article. * [Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?](https://pubmed.ncbi.nlm.nih.gov/40715995/) Patel Y, Chawla J, Parmar MS.Patel Y, et al.Curr Oncol Rep. 2025 Sep;27(9):1070-1079. doi: 10.1007/s11912-025-01704-z. Epub 2025 Jul 26.Curr Oncol Rep. 2025.PMID: 40715995 Review. * [Wonder drugs and where to use them: a forecast of ivermectin's impact on malaria in Africa.](https://pubmed.ncbi.nlm.nih.gov/40689270/) Greenhalgh S, Roman A, Provencher A.Greenhalgh S, et al.Infect Dis Model. 2025 Jun 27;10(4):1229-1237. doi: 10.1016/j.idm.2025.06.003. eCollection 2025 Dec.Infect Dis Model. 2025.PMID: 40689270 Free PMC article. * [Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.](https://pubmed.ncbi.nlm.nih.gov/33038449/) Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L.Formiga FR, et al.J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7.J Control Release. 2021.PMID: 33038449 Free PMC article.Review. ## Cited by * [Ivermectin treatment for gynecologic cancers-Hope versus hype.](https://pubmed.ncbi.nlm.nih.gov/40896730/) Straughn JM Jr.Straughn JM Jr.Gynecol Oncol Rep. 2025 Aug 5;60:101920. doi: 10.1016/j.gore.2025.101920. eCollection 2025 Aug.Gynecol Oncol Rep. 2025.PMID: 40896730 Free PMC article.No abstract available. ## References 1. 1. “Find NCI-Supported Clinical Trials.” National Cancer Institute , [www.cancer.gov/research/participate/clinical-trials-search](http://www.cancer.gov/research/participate/clinical-trials-search "External link: www.cancer.gov/research/participate/clinical-trials-search"). (Accessed 29 May 2025). 2. 1. A Phase I/Ii Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with Expansion Cohort in Pd-L1 Negative Tnbc. Translated by Inc Agenus and Research Gateway for Cancer, 2022. Accessed May 18, 2025. [https://clinicaltrials.gov/study/NCT05318469?cond=ivermectin%20cancer&ra...](https://clinicaltrials.gov/study/NCT05318469?cond=ivermectin%2520cancer%26rank=2 "External link: https://clinicaltrials.gov/study/NCT05318469?cond=ivermectin%20cancer&rank=2"). 3. 1. Blum, D. What Ivermectin Can (and Can’t) Do. The New York Times , Published March 31 2025, Accessed June 5, 2025. [www.nytimes.com/2025/03/31/well/ivermectin-cancer-covid.html](http://www.nytimes.com/2025/03/31/well/ivermectin-cancer-covid.html "External link: www.nytimes.com/2025/03/31/well/ivermectin-cancer-covid.html"). 4. 1. Crump A., Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2011;87(2):13–28. doi: 10.2183/pjab.87.13. - [DOI](https://doi.org/10.2183/pjab.87.13) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3043740/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/21321478/) 5. 1. Donfo-Azafack C., Nana-Djeunga H.C., Wafeu-Sadeu G., Dongmo-Yemele R., Kamgno J. Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report. J. Med. Case Reports. 2023;17(1):141. doi: 10.1186/s13256-023-03891-4. - [DOI](https://doi.org/10.1186/s13256-023-03891-4) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10108531/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/37062821/) ## Publication types * Actions ## LinkOut - more resources * ### Full Text Sources * [Elsevier Science](https://linkinghub.elsevier.com/retrieve/pii/S2352-5789(25)00128-6) * [PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/pmid/40851910/)